Which statement about Phenelzine is true?

Which statement about Phenelzine is true?

• A. Nystagmus is a defining feature
• B. PSC formation is common
• C. Angle closure glaucoma can occur
• D. Lethargy is the primary concern

Answer: (C)

Phenelzine can rarely trigger angle-closure glaucoma in people who have a predisposed eye anatomy with a narrow anterior chamber angle. The drug’s effects on neurotransmission can lead to pupillary dilation; in someone with a narrow angle, this dilation can narrow or close the drainage angle, causing a rise in intraocular pressure and acute glaucoma symptoms. That’s why angle-closure glaucoma can occur with phenelzine. Nystagmus is not a typical or defining feature of this drug, PSC formation isn’t associated with MAO inhibitors, and lethargy isn’t the primary safety concern. If a patient has known narrow-angle glaucoma, MAO inhibitors like phenelzine require careful consideration and monitoring, with prompt evaluation of any eye symptoms such as eye pain, redness, or sudden vision changes.

Phenelzine can rarely trigger angle-closure glaucoma in people who have a predisposed eye anatomy with a narrow anterior chamber angle. The drug’s effects on neurotransmission can lead to pupillary dilation; in someone with a narrow angle, this dilation can narrow or close the drainage angle, causing a rise in intraocular pressure and acute glaucoma symptoms. That’s why angle-closure glaucoma can occur with phenelzine.

Nystagmus is not a typical or defining feature of this drug, PSC formation isn’t associated with MAO inhibitors, and lethargy isn’t the primary safety concern. If a patient has known narrow-angle glaucoma, MAO inhibitors like phenelzine require careful consideration and monitoring, with prompt evaluation of any eye symptoms such as eye pain, redness, or sudden vision changes.